Maximally Selected Chi Square Statistics

Miller, Rupert G.; Siegmund, David

doi:10.2307/2529881

Cited by 443 publications

(290 citation statements)

References 7 publications

Supporting

Mentioning

286

Contrasting

Unclassified

Order By: Relevance

“…The time interval for the end point was calculated from the date of operation to the date of death or the first clinical examination or imaging study that indicated locoregional recurrence or distant metastasis. The maximal chi-square method of Miller and Siegmund [17], and Halpern [18] was applied to determine the cutoff value of MTV which best dichotomized all patients into two subgroups with poor or good prognosis in terms of DFS. The same method was also adapted for SUV peak to determine the cutoff point.…”

Section: Resultsmentioning

confidence: 99%

Prognostic Value of Metabolic Tumor Volume Measured by 18F-FDG PET/CT in Locally Advanced Head and Neck Squamous Cell Carcinomas Treated by Surgery

Choi

Yoo

Han

et al. 2010

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose We assessed the prognostic value of metabolic tumor volume (MTV) measured using 18 F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) inpatients with locally advanced head and neck squamous cell carcinoma (HNSCC). Methods We retrospectively reviewed 56 patients (51 men, five women; mean age 56.0±8.8years) who had locally advanced HNSCC and underwent FDG PET/CT for initial evaluation. All patients had surgical resection and radiotherapy with or without concurrent chemotherapy. The peak standardized uptake value (SUV peak ) and MTV of the target lesion, including primary HNSCC andmetastatic cervical lymph nodes, were measured from FDG PET/CT images. We compared SUV peak , MTV, and clinicopathologic variables such as age, Eastern Cooperative Oncology Group (ECOG) performance status, pN stage, pT stage, TNM stage, histologic grade and treatment modality to disease-free survival (DFS) and overall survival (OS). Results On the initial FDG PET/CT scans, the median SUV peak was 7.8 (range, 1.8-19.0) and MTV was17.0 cm 3 (range, 0.1-131.0 cm 3 ). The estimated 2-year DFS and OS rates were 67.2% and 81.8%. The cutoff points of SUV peak 6.2 and MTV 20.7 cm 3 were the best discriminative values for predicting clinical outcome. MTV and ECOG performance status were significantly related to DFS and OS on univariate and multivariate analyses (p<0.05). Conclusion The MTV obtained from initial FDG PET/CT scan is a significant prognostic factor for disease recurrence and mortality in locally advanced HNSCC treated with surgery and radiotherapy with or without chemotherapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Prognostic Value of Metabolic Tumor Volume Measured by 18F-FDG PET/CT in Locally Advanced Head and Neck Squamous Cell Carcinomas Treated by Surgery

Choi

Yoo

Han

et al. 2010

Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…The maximal w 2 method (Halpern, 1982;Miller and Siegmund, 1982;Lausen and Schumacher, 1992) was used to determine which gene expression (optimal cutoff point) best segregated patients into poor-and good-outcome subgroups (in terms of likelihood of response and survival). To determine the corrected P-values on the basis of the maximal w 2 analysis, 2000 bootstrap-like simulations were used in univariate analyses to estimate the distribution of the maximal w 2 statistics under the null hypothesis of no association.…”

Section: Resultsmentioning

confidence: 99%

Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer

Matsubara¹,

Nishina

Yamada³

et al. 2008

Br J Cancer

View full text Add to dashboard Cite

Using laser-captured microdissection and a real-time RT -PCR assay, we quantitatively evaluated mRNA levels of the following biomarkers in paraffin-embedded gastric cancer (GC) specimens obtained by surgical resection or biopsy: excision repair crosscomplementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase (DPD), methylenetetrahydrofolate reductase (MTHFR), epidermal growth factor receptor (EGFR), and five other biomarkers related to anticancer drug sensitivity. The study group comprised 140 patients who received first-line chemotherapy for advanced GC. All cancer specimens were obtained before chemotherapy. In patients who received first-line S-1 monotherapy (69 patients), low MTHFR expression correlated with a higher response rate (low: 44.9% vs high: 6.3%; P ¼ 0.006). In patients given first-line cisplatin-based regimens (combined with S-1 or irinotecan) (43 patients), low ERCC1 correlated with a higher response rate (low: 55.6% vs high: 18.8%; P ¼ 0.008). Multivariate survival analysis of all patients demonstrated that high ERCC1 (hazard ratio (HR): 2.38 (95% CI: 1.55 -3.67)), high DPD (HR: 2.04 (1.37 -3.02)), low EGFR (HR: 0.34 (0.20 -0.56)), and an elevated serum alkaline phosphatase level (HR: 1.00 (1.001 -1.002)) were significant predictors of poor survival. Our results suggest that these biomarkers are useful predictors of clinical outcomes in patients with advanced GC.

show abstract

“…The Spearman's rho method was used to correlate expression levels of TS and ERCC1. The maximal w 2 method of Miller and Siegmund (Miller and Siegmund, 1982) and Halpern (Halpern, 1982) was adapted to determine which cutoff value best dichotomised patients into low-and high-expression TS and ERCC1 subgroups; the Tree method (LeBlanc and Crowley, 1992) was then applied to optimise these cutoff values. The final cutoff values were confirmed by recursive partitioning and amalgamation using S-Plus software, version 6.1 (Statistical Sciences, Seattle, WA, USA).…”

Section: Resultsmentioning

confidence: 99%

ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen

et al. 2008

View full text Add to dashboard Cite

Molecular markers involved in DNA repair can help to predict survival in gastric cancer patients treated with 5-FU plus platinum chemotherapy. Excision repair cross-complementing 1 (ERCC1) and thymidylate synthase (TS) mRNA expression levels were assessed in advanced gastric cancer tumour samples using real-time quantitative PCR in 76 patients treated with a modified FOLFOX (biweekly oxaliplatin plus 5-FU and folinic acid) regimen. Median survival time in patients with low ERCC1 levels was significantly longer than in those with high levels (15.8 vs 6.2 months; Po0.0001). Patients with high TS levels had longer survival than those with low levels (12.2 vs 10.1 months; P ¼ 0.01). Forty-eight patients with low ERCC1 and high TS levels had a median survival of 16.1 months (Po0.0001). The hazard ratio for patients with high ERCC1 expression was 9.4 (Po0.0001). In patients with high mRNA levels of ERCC1, alternative chemotherapy regimens should be considered.

show abstract

Maximally Selected Chi Square Statistics

Cited by 443 publications

References 7 publications

Prognostic Value of Metabolic Tumor Volume Measured by 18F-FDG PET/CT in Locally Advanced Head and Neck Squamous Cell Carcinomas Treated by Surgery

Prognostic Value of Metabolic Tumor Volume Measured by 18F-FDG PET/CT in Locally Advanced Head and Neck Squamous Cell Carcinomas Treated by Surgery

Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer

ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen

Contact Info

Product

Resources

About